by June Kinoshita, FSHD Society The FSHD Canada Foundation, a close partner and fellow traveler of the FSHD Society since its founders Neil Camarta and Craig Kelley first met in… Read More »
FSHD Canada Foundation awards $2.8 million to CTRN
Extraordinary Measures – Understanding the socioeconomic impact of FSHD
An aspect that is often overlooked during drug development is a cost-benefit analysis of a therapeutic treatment. Insurance companies often determine the level of coverage they are willing to provide… Read More »
Artificial intelligence reveals some surprises
Analysis of FSHD registry data overturns prior ideas about genetic and gender factors by Natalie Katz, MD, University of Rochester Facioscapulohumeral muscular dystrophy is a highly variable disease. While we… Read More »
Extraordinary Measures – Many shots on goal
by Jamshid Arjomand, Chief Science Officer With a dozen or more potential FSHD therapies in the drug development pipeline, why is the FSHD Society continuing to invest substantial funds− a… Read More »
Extraordinary measures – An FSHD Society for everyone
by June Kinoshita, FSHD Society Our mission at the FSHD Society is to find treatments and a cure for FSHD—and then make sure everyone in the world who needs it… Read More »